Absci Corporation and St. John’s Cancer Institute entered into a partnership to uncover breakthrough cancer therapies. The partnership will leverage Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to quickly identify new therapeutic candidates with the potential for higher probability of clinical success.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
